Share page on LinkedIn

The promise of decentralised models and diversity in clinical trials

Biopharma perspective

ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently or likely to address diversity and inclusion in clinical trials into the future.

Executive report

Read our summary report for insight into how organisations responded rapidly to the developments in 2020 and how this is paving the way for continuous improvements into the future.

Contact us

For more information on decentralised trials, diversity in clinical trials or to speak with one of our experts, please contact us.

Enquiry form
Insights: Decentralised & hybrid clinical trials

Insights: Decentralised & hybrid clinical trials

Patient focused research for better outcomes

ICON's experts provide insights including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of decentralised & hybrid clinical trials.

Read more